EW Edwards Lifesciences Загрузка... : Бычьи и медвежьи мнения аналитиков
Загрузка графика...
Лучшие сигналы
Лента
12:11
28 июл
28 июл
UBS, Leerink Partners, BofA, JPMorgan, Truist, Exane BNP Paribas.
UBS, Leerink Partners, BofA, JPMorgan, Truist, Exane BNP Paribas, and Wells Fargo issued multiple analyst upgrades and initiations across a range of stocks including Edwards Lifesciences, Enovis, Gossamer Bio, Honeywell, International Paper, Intuitive Surgical, Magnolia Oil & Gas, Nutrien, QXO, and Stryker.
07:18
25 июл
25 июл
Edwards Lifesciences has held its value, beaten earnings estimates, and sees continued growth in minimally invasive heart valves; June sales and earnings also beat. Expanded Medicare coverage and an upcoming clinical trial readout provide catalysts; the stock is still at $84 with analyst target of $100 (19% upside). Edwards is a clean growth story in large-cap medtech at a reasonable valuation, offering relative safety within the sector. Clinical trial miss; Medicare policy changes; competition from newer valve technologies.
Выс.
12:47
24 июл
24 июл
US pre-market movers show Intel up on strong earnings and guidance.
US pre-market movers show Intel up on strong earnings and guidance, American Express down on revenue and profit guidance miss, Oracle up on a Navy contract, and Charter Communications down on broadband subscriber losses.
12:47
24 июл
24 июл
US pre-market movers show Intel up on strong earnings and guidance.
US pre-market movers show Intel up on strong earnings and guidance, American Express down on revenue and profit miss, Oracle up on Navy contract, and Charter down on broadband subscriber decline.
02:39
24 июл
24 июл
JPMorgan raised its price target on Edwards Lifesciences Corp.
JPMorgan raised its price target on Edwards Lifesciences Corp. to $105, up from the previous target of $100.
17:00
23 июл
23 июл
Management raised full-year guidance across all segments, citing durable competitive advantages in TAVR and accelerating TMTT portfolio adoption, signaling confidence in sustained mid-to-high single-digit TAVR growth and 10% total company growth long-term.
Выс.
12:00
16 июн
16 июн
SpaceX выросла на 7,3% на премаркете, акции «Mag 7» торгуются разнонаправленно.
SpaceX выросла на 7,3% на премаркете, акции «Mag 7» торгуются разнонаправленно, Domo упала на 13% на фоне стратегического обзора, Edgewise снизилась на 23% из-за результатов испытаний, Edwards Lifesciences прибавила 3,1% на новости о предложении по покрытию, Huntsman упала на 7% из-за слияния с Olin, а Robinhood выросла на 2% на фоне сокращения штата.
11:45
03 июн
03 июн
The impact of the US low-risk TAVR data is reflected in a flattening of US revenue for this segment, but the company indicates stabilization over last 8 weeks, which could be a short-term bottoming in this market. — Signals a potential bottom in Medtronic's US TAVR market share and could relieve pressure on Edwards Lifesciences if the stabilization holds.
Сред.
14:00
23 апр
23 апр
Management raised full-year guidance across total company, TAVR, and EPS, citing strong Q1 momentum and broad-based growth, signaling improving confidence in the durable multi-year growth trajectory.
Выс.
17:00
10 фев
10 фев
Management expressed heightened confidence in 2026 guidance (8-10% sales growth, $2.90-$3.05 EPS) citing strong Q4 momentum, multiple growth catalysts, and durable evidence-driven tailwinds.
Выс.
21:30
04 фев
04 фев
The 50 new programs added across 43 unique brands in the biopharma services segment, and the digitization of enrollment for more than 1,600 specialty drugs, points to a structural volume ramp in the prior authorization space. — This positions McKesson's PTS segment as the 'plumbing' for prior authorizations, having scale advantages that are hard to replicate, and is a volume story independent of specific drug class (e.g., oral GLP-1s).
Сред.
17:00
30 окт
30 окт
Management raised full-year guidance on the back of stronger-than-expected Q3, citing renewed clinical focus on TAVR and positive data; tone is confident about sustainable multi-year growth.
Выс.
Об аналитическом покрытии EW
Buzzberg отслеживает EW (Edwards Lifesciences) в 6 источниках. Бычьих сигналов: 1, медвежьих: 0, от 9 аналитиков. Сентимент преимущественно бычий (8%). Всего отслеживается 12 торговых идей. Последние спикеры: DeItaone, u/raytoei, Newsquawk.